What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.